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To assess the clinical utility of replacing microbial culture forNeisseria gonorrhoeaewith a nucleic acid amplification test
(NAAT), we comparedN. gonorrhoeae culture with the cobas 4800 CT/NG test for 18,247 urogenital and 666 nongenital samples.
For urogenital specimens, the sensitivity, specificity, and positive and negative predictive values of the cobasN. gonorrhoeae
PCR were 98.7%, 100%, 95.6%, and 100%, respectively, and for nongenital specimens, the values were 100%, 99.8%, 92.9%, and
100%, respectively. In our test population, 37% (10,185) of patients tested over the study period were screened for C. trachoma-
tis by PCR but were not screened for gonorrhea by culture. Of these, 43 wereN. gonorrhoeae positive by PCR and therefore went
undiagnosed. The cobas 4800 CT/NG test diagnosed 33% (n 30) more urogenital and 25% (n 3) more rectal gonorrhea infec-
tions than culture and, based on the above performance indicators, does not require supplementary testing for urogenital or
rectal specimens. The ability to test noninvasive specimens (such as urine and self-taken vulvovaginal swabs) forN. gonorrhoeae
will enable more patients to be screened for infection, thus offering significant positive public health benefits.
Nucleic acid amplification tests (NAATs) have been recom-mended for the diagnosis of Chlamydia trachomatis in New
Zealand since 2008 (1). However, problems with the specificity of
particular NAATs for Neisseria gonorrhoeae (2, 3) meant that mi-
crobial culture remained the method of choice in New Zealand’s
low-prevalence population (67 per 100,000) (4). Well-established
clinical advantages of NAATs for diagnosing sexually transmitted
infections (STIs), including higher sensitivity, detection of nonvi-
able organisms, and testing of noninvasive specimens, are driving
a change to molecular testing. Replacement of culture with auto-
matedNAATs brings significant workflow benefits, a reduction in
reporting time, and the ability to test a single specimen for bothC.
trachomatis and N. gonorrhoeae. Also, the positive public health
impacts of a higher number of cases being diagnosed are impor-
tant for tackling increasingly difficult-to-treat gonorrhea infec-
tions.
Universal screening usingNAATs for samples fromnongenital
sites, particularly those from men who have sex with men, is en-
couraged, to minimize the morbidity associated with gonorrhea
and potentially to enhance control ofHIV transmission (5). How-
ever, there may be issues with the specificity of NAATs performed
on samples from these anatomic sites due to the potential presence
of commensal Neisseria species (6, 7).
Since 2009, C. trachomatis testing in our laboratory has been
performed on the cobas 4800 using the C. trachomatis/N. gonor-
rhoeae PCR test (Roche Diagnostics, New Zealand), which simul-
taneously detectsC. trachomatis andN. gonorrhoeae. However, the
N. gonorrhoeae test was not initially reported, and culture was
maintained for detection of gonorrhea. Recent studies report im-
proved clinical and analytical specificity of the cobas 4800N. gon-
orrhoeae assay over previous assays (8, 9), indicating that N. gon-
orrhoeae confirmatory testing may not be required on some
specimens (10). This study compared the cobas 4800 N. gonor-
rhoeae test to culture, for genital and nongenital specimens, to
investigate whether its performance would be acceptable without
supplementary confirmatory testing in our low-prevalence popu-
lation.
MATERIALS AND METHODS
Study design. We retrospectively compared culture and cobas 4800 N.
gonorrhoeae results obtained for patients from whom 2 specimens were
collected; a cervical or urethral swab taken by a physician for microbial
culture, and a physician-taken cervical, urethral, rectal, or throat swab or
a urine sample or self-taken vulvovaginal swab for C. trachomatis PCR
between 1 January 2011 and 13 September 2011. N. gonorrhoeae PCR
results were obtained from the raw data (extensible markup language
[XML] files) generated by the cobas 4800 for all C. trachomatis specimens
tested, with the assistance of Roche Diagnostics, New Zealand.
Testing methods. Amies medium swabs and direct cultures were in-
oculated ontoNew York City (NYC) or ThayerMartin agar (Fort Richard
Laboratories) and incubated in 5% CO2 at 37°C for 48 h. Isolates sus-
pected of being N. gonorrhoeae were identified by Gram staining and
oxidase testing and confirmed using BactiCard (Remel, Lenexa, KS),
and/orMicroTrakDirect fluorescence antibody test (Syva, PaloAlto, CA).
Specimens submitted for routine C. trachomatis NAAT analysis were
tested on the cobas 4800 as per the manufacturers’ protocol (11) with the
exception that swab specimens were vortexed for 1 min and the swabs
removed prior to testing. Physician-collected nongenital swab specimens
were processed in the same manner as genital swabs. The recommended
procedure for collection of rectal swabs is via a proctoscope, and for pha-
ryngeal specimens, swabs should be taken from the back of the throat/
tonsillar area.
Testing forN. gonorrhoeaewas simultaneously performed by the cobas
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4800; however, the results forN. gonorrhoeae were not reported clinically
during the study period. Any specimen with a nonvalid result (i.e., failure
due to a pipetting error or a clot in the specimen or an invalid result due to
amplification failure) was treated with Sputasol (1.4% dithiothreitol
[DTT]; Oxoid, Basingstoke, United Kingdom) and retested as previously
described (12).
Urine specimens were not cultured for N. gonorrhoeae in our labora-
tory but were tested for C. trachomatis by PCR; therefore, when a urine
specimenwas sent forC. trachomatis testing, an accompanying cervical or
urethral culture swab result was compared (referred to as urogenital spec-
imens) (n 18,247).
Assay performance was further investigated using 97 local isolates
grown from directly inoculated plates (from Wellington sexual health
clinics) or from swabs from the rectum (n 24), throat (n 32), urethra
(n 26), penis (n 2), and cervix (n 13) that were received in Amies
transport medium and inoculated onto NYC agar.
Analytical specificity panel.Analytical specificity was evaluated using
6 gonococcal and 34 commensal or pathogenic bacterial and fungal iso-
lates grown from reconstituted freeze-dried organisms from the Institute
of Environmental Science and Research, Limited (ESR), culture collec-
tion. Gonococcal isolates included antibiotic-sensitive and -resistant
strains: ATCC 43069 (medium quality control strain), ATCC 49226 (an-
tibiotic sensitivity reference strain), AGSP QC 00/3 (ciprofloxacin MIC,
2.0 mg/liter), AGSP QC 36 (penicillin MIC, 2.0 mg/liter), AS 84/417 (NZ
plasmid), AS 91/376 (tetracycline MIC  16 mg/liter; penicillinase pro-
ducing). N. meningitidis isolates included a representative strain from
each of groups A, B, andC. Also includedwereAcinetobacter calcoaceticus,
Candida albicans, Candida glabrata, Citrobacter freundii, Enterococcus
faecalis, Enterococcus faecium, Escherichia coli, Fusobacterium necropho-
rum,Gardnerella vaginalis,Haemophilus influenzae (n 3),Haemophilus
parainfluenzae, Klebsiella pneumoniae, Lactobacillus acidophilus, Micro-
coccus luteus,Neisseria cinerea,N. flava,N. lactamica,N.meningitidis (n
3), N. sicca, N. subflava, Proteus mirabilis, Serratia marcescens, Streptococ-
cus agalactiae, S. pneumoniae, S. viridans, Staphylococcus aureus (n 2), S.
epidermis, S. pyogenes, and S. saprophyticus. Organisms were grown on
tryptic soy agar with sheep blood, supplemented chocolate agar, or Sab-
ouraud dextrose agar with antibiotics (Fort Richard Laboratories, Auck-
land,NZ) under optimal conditions (36°C and 5%CO2 or 36°C andO2 or
under anaerobic conditions [ANO2] for 24 to 48 h).
A pure isolate of each organismwas inoculated into sterile saline to 0.5
McFarland standard turbidity (approximately 1 108 CFU/ml of bacte-
ria). A 50-l portion of the resulting mixture was added to a 4.2-ml tube
of cobas PCRmedium. Panels included 2 to 5 organisms per tube of cobas
PCR medium.
Confirmatory testing.Where results were discordant between culture
and PCR, available specimens were sent for testing at the Queensland
Pediatric Infectious Diseases (QPID) laboratory, Brisbane, Australia.
DNA was extracted with a MagNA Pure LC system (Roche) using a total
nucleic acid isolation kit (Roche) and then sent for confirmatory testing
by a N. gonorrhoeae duplex PCR test targeting the porA pseudogene and
opa genes (8, 13).
Discrepancy analysis. This study was a retrospective audit; therefore,
some specimens with discrepant results were not available for testing. A
board-certified microbiologist determined the expected results for these
specimens by reviewing available clinical information under the following
criteria. Specimenswere ruled positive if therewas previous or subsequent
testing history of an N. gonorrhoeae-positive result (by culture and/or
PCR), clinical details from the referrer indicated probableN. gonorrhoeae
infection, the N. gonorrhoeae PCR specimen tested positive by supple-
mentary testing for porA/opa gene targets, a companion specimen tested
N. gonorrhoeae positive (by culture and/or PCR), or if the patient was a
sexual contact of a patient diagnosed withN. gonorrhoeae infection. Spec-
imens were ruled negative if there was no clinical history/possibility of
infection or if culture was performed on an inappropriate anatomical site
(e.g., external genitalia). As culture was considered the gold standard for
this evaluation, where no information was available, discrepant PCR re-
sults were ruled false.
RESULTS
Between 1 January 2011 and 13 September 2011, 27,585 speci-
mens were tested on the cobas 4800 for C. trachomatis, of which
187 (0.68%) were positive for N. gonorrhoeae during our retro-
spective analysis. During the same period, 144/18,789 (0.77%)
(unpaired) cultures grew N. gonorrhoeae.
C. trachomatis samples with valid results were separated into
“orphan C. trachomatis specimens” (where there was no request
for N. gonorrhoeae culture [n 10,185]) and “study specimens,”
which were accompanied by a request for N. gonorrhoeae culture
(n 17,400), and direct culture plates (n 97). As multiple sites
were tested for some patients, there were 18,913 specimens with
comparable test results, including 16,692 genital swabs, 1,555
urine specimens, and 531 rectal, 19 throat, and 84 eye swabs. Non-
genital sites are not validated for testing on the cobas 4800 by the
manufacturer. However, a significant proportion of specimens
from sexual health clinics are from these sites; therefore, it was
important to analyze assay performance in these specimen types.
A total of 79/187 (42.2%) patients infected with N. gonorrhoeae
were found to be coinfected with C. trachomatis at the time of
testing. In contrast, only 79/2,165 (3.6%) of patients infected with
C. trachomatis were positive for N. gonorrhoeae.
Samples with failed or invalid cobas 4800 results were excluded
from the analysis of assay performance.
Assay performance. The performance of the cobas 4800 N.
gonorrhoeae assay was assessed by comparing validN. gonorrhoeae
PCR results withmicrobial culture for 17,400 specimens tested on
the same day.
These data showed 122 concordant N. gonorrhoeae positive
results and a further 37/17,400 (0.2%) discrepant results. Of the
discrepant cobas specimens, 35 were PCR positive and culture
negative (5 urine specimens and 24 cervical, 1 urethral, 1 penile, 1
vaginal, and 3 rectal swabs) and 2 were PCR negative and culture
positive (both urine specimens).
Before the resolution of discrepant results, the sensitivity, spec-
ificity, and positive and negative predictive values for the perfor-
mance of the cobas 4800 CT/NG test for urogenital specimens
were 98.5% (95% confidence interval, 94.6% to 99.8%), 99.8%
(99.7% to 99.9%), 80% (73.0% to 85.9%), and 100% (99.9% to
100%), respectively. For nongenital specimens the sensitivity,
specificity, and positive and negative predictive values were 100%
(71.5% to 100%), 99.5% (98.7% to 99.9%), 78.6% (49.2% to
95.3%), and 100% (99.4% to 100%), respectively.
Further testing and analysis. There were 10 samples with dis-
crepant results (N. gonorrhoeae positive by PCR but negative by
culture) available for confirmatory PCR testing at QPID. The co-
bas N. gonorrhoeae results were considered correct if the sample
tested positive for the porA and/or opa targets. In total, 9 samples
were positive by these criteria, while 1 was not confirmed. All
remaining discrepant results were evaluated by the clinical micro-
biologist with regard to history, clinical details, and companion
specimen results.
Of the 37 discrepant samples, 27 positive PCR results were
confirmed, while 2 results were ruled false negative and 8 were
ruled false positive.
In total, there were 164 samples with concordant N. gonor-
rhoeae-positive results and 18,739 samples with concordant neg-
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ative results (Table 1). The assay performance was recalculated
and showed that for urogenital specimens, the sensitivity, speci-
ficity, and positive and negative predictive values were 98.7%
(95% confidence interval, 95.4% to 99.8%), 100% (99.9% to
100%), 95.6% (91.1% to 98.2%), and 100% (99.9% to 100%),
respectively. For nongenital specimens the sensitivity, specificity,
and positive and negative predictive values were 100% (75.3% to
100%), 99.8% (99.1% to 100%), 92.9% (66.1% to 99.8%), and
100% (99.4% to 100%), respectively (Table 2).
A separate analysis of performance in the 564 urine specimens
from females and 950 from males showed that the cobas 4800 N.
gonorrhoeae test has a sensitivity of only 86.7% for female urine
specimens compared to cervical or urethral swab culture, while it
has 100% sensitivity for male urine specimens compared to ure-
thral swab culture (Table 3).
Missed opportunities for screening and diagnosis. A total of
10,185 (37%) of C. trachomatis specimens in the study were not
accompanied by a culture swab for gonorrhoea andwere excluded
from the analysis of assay performance. However, of these speci-
mens, 43 wereN. gonorrhoeae positive by PCR (8 vaginal swabs, 6
cervical swabs, 1 penile swab, 1 urethral swab, and 27 urine spec-
imens), with 36 of these 43 being “noninvasive” specimen types.
Only 1,389 (7.4%) of gonorrhoea culture specimens were not ac-
companied by a swab for C. trachomatis PCR.
During the period of the study, the number of extra infections
that were identified by PCR was 65 (35%). These results were
referred to the clinical microbiologist for interpretation.
Specificity. The analytical specificity of the cobas 4800 C. tra-
chomatis/N. gonorrhoeae assaywas first determined for local gono-
coccal isolates, including both antibiotic-resistant and -sensitive
strains, including a N. gonorrhoeae prolyl iminopeptidase (PIP)-
negative clinical isolate (14). All were identified correctly as posi-
tive for N. gonorrhoeae. A further 34 reference laboratory organ-
isms (including nongonococcal neisseriae and commensal and
pathogenic bacterial and fungal isolates) were tested and correctly
identified as negative by this assay.
DISCUSSION
For routine supplementary confirmatory testing not to be neces-
sary, the performance indicators of specificity and PPV should
reach 95% and 90%, respectively, which can be difficult in a
low-prevalence population (15, 16). As prevalence decreases, PPV
decreases, and therefore, the likelihood of a false-positive result
increases and the effect of test specificity is magnified. Our test
population exhibited a low frequency ofN. gonorrhoeae infections
as determined by culture (0.77%, data not shown), which is com-
parable to the reported national test positivity rate of 0.8% inNew
Zealand (4). Previous reports have shown that 35 to 41% of pa-
tients may be coinfected with C. trachomatis and N. gonorrhoeae
(17), and we found that 42.2% of those infected with N. gonor-
rhoeae had a concurrentC. trachomatis infection. These high rates
of coinfection confirm the importance of testing for both STIs,
and the ability to test both organisms from a single specimen is a
benefit of multiplex NAAT tests.
The performance of the cobas 4800 N. gonorrhoeae assay was
assessed by comparison with culture in 18,905 paired specimens
obtained from 17,400 visits, and we initially found 37 (0.2%) dis-
crepant results between PCR and culture. Ten of these samples
were available for supplementary confirmatory testing, of which 9
were positive for both opa and porA, and 1 did not give consistent
results (presumably due to low organism load). After supplemen-
tary testing and clinical review of the remaining discrepant sam-
ples, 10 were deemed to have false N. gonorrhoeae PCR results (8
false positives, 2 false negatives).
The performance indicators calculated from these data
reached 95% sensitivity and specificity and 90% PPV and
NPV. Notably, our PPV reached 95.6% in urogenital specimens
and 92.9% in nongenital specimens. However, it should be noted
TABLE 2 Performance of the cobas 4800 N. gonorrhoeae assay by specimen type (after discrepancy resolution)a
Specimen n Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Urogenital
All 18,247 98.7 (95.4–99.8) 100 (99.9–100) 95.6 (91.1–98.2) 100 (99.9–100)
Female 16,605 97.5 (91.4–99.7) 100 (99.9–100) 91.9 (83.9–96.7) 100 (99.9–100)
Male 1,642 100 (95.0–100) 100 (99.7–100) 100 (95.0–100) 100 (99.7–100)
Nongenital
All 666 100 (75.3–100) 99.8 (99.1–100) 92.9 (66.1–99.8) 100 (99.4–100)
Female 86 100 (2.5–100) 100 (95.7–100) 100 (2.5–100) 100 (95.7–100)
Male 580 100 (73.5–100) 99.8 (99.0–100) 92.3 (64.0–99.8) 100 (99.3–100)
Total 18,913 98.8 (95.7–99.9) 100 (99.9–100) 95.3 (91.0–98.0) 100 (99.9–100)
a 95% confidence intervals are provided in parentheses.
TABLE 1 N. gonorrhoeae PCR results compared to culture following
discrepancy analysis and resolution
Sample PCR result
No. of patients (M/F)a
Culture positive Culture negative
Urogenital  151 (79/72) 7 (F)
 2 (F) 18,087 (16,517/1570)
Rectal  12 (1/11) 1 (M)
 0 518 (24/494)
Throat  1 (M) 0
 0 50 (9/41)
Eye  0 0
 0 84 (11/73)
a M, male; F, female.
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that a limitation and potential bias of this study was that the PCR
and culture were, for the most part, not performed on the same
sample type (i.e., PCR was performed on urine samples and bac-
terial culture on genital swabs). Nevertheless, our findings are
supported by two recent studies which showed that the cobas N.
gonorrhoeae test had lower levels of false positivity than predeces-
sor assays (9) and does not require a confirmation test for N.
gonorrhoeae in urine specimens (10).
Despite recent calls tomove to NAAT routinely for pharyngeal
and rectal testing, it is still recommended that positive results from
these sites be confirmed by supplemental assays (5). The presence
of potentially cross-reacting commensal Neisseria species in non-
genital sites may compromise the specificity of NAATs, and the
cobas 4800 CT/NG test is not commercially validated for these
specimen types. While our results showed that that there was no
cross-reactivity with either local or reference laboratory strains of
commensal Neisseria species, it should be noted that we tested
only limited numbers of throat samples (n  51) compared to
rectal samples (n  531) and had no positive eye swabs in the
validation. Therefore, supplementary testing of cobas 4800 N.
gonorrhoeae-positive results for throat and eye samples is still war-
ranted (13).
While different sample types were used for much of the PCR
and culture-based testing, the results suggest that if PCR were the
gold standard test against which the sensitivity of culture was as-
sessed, the sensitivity of culture for urogenital and nongenital
specimens would be low, at 80% and 79%, respectively. The poor
sensitivity of culture may contribute not only to a higher preva-
lence of gonorrhea but also to higher rates of HIV transmission
(5). The limited sensitivity of culture compared with NAAT, par-
ticularly for pharyngeal and rectal samples, is well substantiated
(6, 7, 18).
Self-taken swabs and urine samples are now widely used for C.
trachomatis testing, but in our laboratory, culture for N. gonor-
rhoeaewas carried out only on cervical, urethral, throat, and rectal
swabs. The comparative difficulty of obtaining invasive specimens
may have led to a decrease in testing for N. gonorrhoeae.
This is evidenced by the one-third of patients who provided
“noninvasive” specimens for C. trachomatis PCR testing but no
culture specimen during the study period. Indeed, 43 of these
patients were found to be positive for gonorrhoea by N. gonor-
rhoeae PCR, with the majority of these results (36/43) coming
from “noninvasive” specimen types.
The cobas 4800 N. gonorrhoeae PCR assay has several limita-
tions. As in previous studies on C. trachomatis/N. gonorrhoeae
NAAT assays, our data show that a urine specimen alone is not
sufficiently sensitive (86.7%) to screen for N. gonorrhoeae in fe-
males (19, 20). We have previously shown that interference from
mucopurulent discharge in N. gonorrhoeae-positive patients
causes failed cobas 4800 results (12), and this has also been re-
ported by Hopkins et al. (10). Most failed results can be resolved
by treatment with Sputasol (1.4% DTT; Oxoid) (12). Methods to
overcome this technical problem are essential to the reliable use of
the cobas 4800 C. trachomatis/N. gonorrhoeae assay when second-
ary assays are not available. Extensively drug-resistant (XDR) N.
gonorrhoeae strains displaying high-level resistance to third-gen-
eration cephalosporins (ceftriaxone and cefixime) may pose a
problem for transferringN. gonorrhoeaediagnosis toNAATmeth-
ods and empirically treating patients. Therefore, enhanced sur-
veillance of antibiotic susceptibility is recommended (21, 22).
However, maintaining a viable organism for this testing is not
possible in the high-salt cobas PCR collectionmedium. Until mo-
lecular methods for detection of gene sequences that confer resis-
tance are validated for routine laboratory use, testing by both cul-
ture and PCR of N. gonorrhoeae is required to continue
surveillance of antibiotic susceptibility (23). The challenge in a
diagnostic laboratory arises when it is not economically viable to
provide both tests. The question of whether diagnostic sensitivity
is subordinate to antimicrobial resistance surveillance in this sit-
uation remains to be answered.
In summary, this audit comprehensively evaluated the perfor-
mance of the cobas 4800CT/NG test forN. gonorrhoeae compared
to microbial culture. The cobas 4800 CT/NG test diagnosed 33%
more urogenital and 25% more rectal N. gonorrhoeae infections
than culture, and, based on performance indicators, neither uro-
genital nor rectal specimens require supplementary confirmatory
testing in our low-prevalence population.
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